In 2005, Aché acquired Biosintética Farmacêutica. This acquisition is part of Aché?s strategic plan, which was established in 2004, which aims for, amongst other things, sustained growth, leadership of the domestic market, greater capacity for investment in innovation, and strengthening of the product portfolio. The complementary portfolio and cultural similarities of the two companies were the main factors that led to the acquisition of Biosintética.

With this integration, Aché now had 250 therapeutic alternatives and the company moved into new segments such as the cardiovascular area and generic medicines, and the expanded its portfolio in the central nervous system, dermatology, respiratory, oncology and generic medicine areas.

Why not visit the Genéricos Biosintética website? -